Navigation Links
Dr. Daniel Ronel Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler
Date:7/10/2009

SANTA FE and ALBUQUERQUE, N.M., July 10 /PRNewswire/ -- Daniel Ronel, M.D., a board-certified plastic surgeon, has selected Artefill, the first and only FDA-approved microsphere-enhanced collagen filler for the correction of smile lines, to treat patients who are looking for a longer lasting dermal filler. Dr. Ronel has been an avid Artefill user the past several years due to its proven success and effectiveness for the correction of wrinkles.

He says, "My patients love the fact that their wrinkle correction can last for years with Artefill, and I enjoy using it because it is silky smooth, versatile, and clear. In this economy, people are grateful that they do not need to come back repeatedly to pay for more filler! I have found that each syringe of Artefill goes a long way."

This simple, in-office procedure takes approximately fifteen minutes to complete. A patient is injected with Artefill similar to other dermal fillers with the key difference being its lasting effect. The unique microspheres in Artefill are not absorbed by the body and therefore provide the support the skin needs for long lasting natural feeling results. This is different from temporary dermal fillers that are made of different kinds of natural or synthetic materials that are completely absorbed by the body over time and require repeat injections to maintain wrinkle correction. A skin test is required prior to treatment or approximately four (4) weeks ahead of time, to ensure a patient is not allergic to the collagen or anesthetic in Artefill.

Artefill is only offered by a select group of physicians in the Southwest and is not available at all physician offices. Dr. Ronel is one of the company trained and select few company sponsored physicians who has the skills and experience needed to administer the product.

Elizabeth Ferrell, a patient of Dr. Ronel's said, "Artefill was the logical choice for me -- I've had deep lines ever since I was a teenager and I was frustrated at having to go back and forth for more injections. Dr. Ronel's technique, with all the holistic things he does, actually made the whole experience pleasant. My family and friends were very impressed, and felt the same way after they went in themselves."

About Artefill:

Artefill is the first and only FDA-approved microsphere-enhanced collagen filler for the correction of nasolabial folds, better known as smile lines. The safety and effectiveness of Artefill has been extensively studied over the past eight years. Since Artefill was approved in 2006, over 10 thousand patients have been treated successfully with very high satisfaction rates.

Suneva Medical, Inc., a medical technology company focused on developing, manufacturing and commercializing novel, differentiated aesthetic products for the dermatology, plastic and cosmetic surgery markets, markets and manufactures Artefill. The Company was formed in April 2009 to deliver the same great product that physicians and patients have embraced over the past several years. For more information visit www.artefill.com or www.sunevamedical.com.

DR. DANIEL RONEL is a board-certified plastic surgeon with offices in Santa Fe and Albuquerque NM. Educated and trained at Princeton, Penn, Columbia, Cornell, and Harvard, he is the only surgeon in the U.S. who is board certified in both plastic surgery and pediatrics. Dr. Ronel was named one of America's Top Plastic Surgeons by the Consumer's Research Council of America. Because of his combined expertise in pediatrics and plastic surgery, Dr. Ronel is one of 13 national experts selected by Allergan to sit on the Breast Implant Research Team, an advisory panel on silicone breast implants. Dr. Ronel is a member of the Radiesse Medical Education Facility, a group composed of approximately 120 physicians from across the United States who are experts in the field of injectable fillers. He was voted Albuquerque's Plastic Surgeon of the Year in 2007 by readers of The Herald, and was named one of Albuquerque's 2007 Top Docs by Albuquerque, the Magazine. He can be found on the web at www.danielronelmd.com.

ATTENTION MEDIA: To download Artefill patient before and after pictures visit http://www.artefill.com/content/c/beforeandafter/overview.asp

    Contact:
    Daniel Ronel, M.D.
    Office: 505-982-2440
    Cell: 505-690-5337
    info@danielronelmd.com


'/>"/>
SOURCE Daniel Ronel, M.D.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
2. PPD Names Daniel Darazsdi as Chief Financial Officer
3. OmniSonics Appoints J. Daniel Cole Chairman of the Board
4. Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board
5. Ikaria Appoints Daniel Tasse as President and Chief Executive Officer
6. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
7. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
8. Anesiva Appoints Daniel Janney to Board of Directors
9. Egenix, Inc. Appoints Dr. Daniel Petrylak Chairman of Scientific Advisory Board
10. Daniel B. Dubin, M.D., Joins NanoBio Corp.s Board of Directors
11. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... The Society ... research agencies as outlined in the Administration’s recently published fiscal year 2018 budget request. ... National Institutes of Health (NIH) by $5.8 billion or roughly 20% of its total ...
(Date:3/22/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... Chaim Lebovits , Chief Executive Officer, will provide an ... Sachs Associates 2 nd Annual Neuroscience Biopartnering and ... at the New York Academy of Sciences. ...
(Date:3/22/2017)... MARLBOROUGH, Mass. , March 22, 2017 /PRNewswire/ ... company developing innovative therapeutics that address significant unmet ... PhD, RXi,s Chief Business Officer, will present at ... The forum will provide a platform to present ... research institutes, leading pharmaceutical and biotech companies as ...
(Date:3/20/2017)... ... March 20, 2017 , ... SSCI and Whitehouse Laboratories, divisions of Albany ... ! Sponsored by the Parenteral Drug Association (PDA), the New York Interphex Show ... professionals in attendance and more than 625 exhibitors, the educational and networking opportunities are ...
Breaking Biology Technology:
(Date:2/26/2017)... Feb. 25, 2017  Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring, announces ... Reentry. "Too often, too many offenders ... county jails are trying to tackle this ongoing ... friends and family members. While significant steps are underway, ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special ... Kephart of Identity Strategy Partners, LLP, today releases ... "Executive Order: Protecting the Nation From Foreign Terrorist Entry ... "As President Trump,s ,Travel Ban, Executive Order gains more ... the travel ban, it is important that our national ...
Breaking Biology News(10 mins):